Browse the evidence

Lipopolysaccharide (LPS) translocation from the gut to the blood (metabolic endotoxemia) is a key driver of systemic inflammation, mediated by the TLR4 receptor, and is directly caused by HFD-induced gut barrier dysfunction.

To reduce systemic inflammation, it is not enough to just eat less; you must also protect your gut lining to prevent bacterial toxins (LPS) from entering your bloodstream and triggering an immune response.

Testosterone replacement therapy in middle-aged and older men significantly increases the risk of elevated hematocrit (>50%) and prostate events compared to placebo.

If you are an older man considering testosterone therapy, expect your blood thickness (hematocrit) and prostate markers (PSA) to rise. You must commit to regular blood tests and prostate exams. The risk of heart attacks or death does not appear to increase significantly, but the risk of thick blood and prostate issues does.

Hyperglycemia in Type 2 Diabetes Mellitus causes endothelial dysfunction and platelet hyperactivity through oxidative stress, AGE formation, and PKC activation, leading to accelerated atherosclerosis.

For T2DM patients, controlling blood sugar is not enough to prevent heart disease. You must address the underlying vascular damage caused by high glucose and insulin resistance. This involves managing oxidative stress and inflammation through medication (like SGLT2 inhibitors or GLP-1 agonists mentioned in the text) and lifestyle changes, not just glucose monitoring.

Inhibition of Acetyl-CoA Carboxylase 2 (ACC2) reduces malonyl-CoA levels, thereby removing inhibition on CPT1, which increases fatty acid oxidation, reduces intracellular lipid accumulation, and improves insulin sensitivity in muscle and liver.

Targeting the ACC2 enzyme to lower malonyl-CoA levels appears to be a highly effective strategy for improving insulin sensitivity and reducing liver fat. By preventing the inhibition of fat transport into mitochondria (via CPT1), the body can burn fat more efficiently, which in turn lowers the toxic lipid byproducts that cause insulin resistance. This suggests that therapies aimed at ACC2 inhibition could treat obesity and type 2 diabetes by restoring the body's ability to burn fat.

Chronic obesity causes adipose tissue dysfunction through a triad of unresolved inflammation, fibrosis, and impaired angiogenesis, driven by persistent hypoxia and adipocyte death.

Obesity is not just about having too much fat; it is about the fat tissue becoming sick due to lack of oxygen, inflammation, and scarring. Simply losing weight might not fix these underlying tissue issues if the diet and lifestyle don't support healthy tissue remodeling. Focus on strategies that improve metabolic health and reduce inflammation, not just scale weight.

Hypoxia in expanding adipose tissue drives a complex response involving both pro-angiogenic and pro-fibrotic pathways, with HIF-1α playing a dominant pro-fibrotic role in obesity.

Low oxygen levels in fat tissue are a double-edged sword. They try to create new blood vessels, but they also trigger scarring and inflammation. In obesity, the scarring and inflammation often win out, worsening metabolic health.

Cellular senescence in adipose tissue contributes to obesity-associated dysfunction through the secretion of pro-inflammatory factors (SASP) and impairment of angiogenesis.

Obesity can cause fat cells to age prematurely and secrete harmful substances that damage surrounding tissue. Managing obesity may help reduce this cellular aging and its negative effects.

Elevated alanine aminotransferase (ALT) levels in nondiabetic individuals are associated with decreased hepatic insulin sensitivity and predict the future development of type 2 diabetes, independent of obesity and whole-body insulin resistance.

If you have elevated ALT, even within the standard 'normal' lab range, it may signal reduced liver insulin sensitivity and a higher risk of developing type 2 diabetes. This is particularly relevant if you have high body fat. Focus on improving hepatic insulin sensitivity through weight management and metabolic health, as ALT serves as an early warning marker independent of whole-body insulin resistance.

Short-term intensive insulin therapy administered at diagnosis of type 2 diabetes can restore beta-cell function and induce temporary remission.

If you have just been diagnosed with type 2 diabetes, ask your doctor about short-term intensive insulin therapy. This approach can 'rest' your pancreas, improve its function, and potentially put your diabetes into temporary remission, especially if caught early.

Thiazolidinediones (TZDs) preserve beta-cell mass and function by reducing apoptosis and islet amyloid, acting via PPAR-gamma activation.

TZDs are a class of drugs that can help protect your pancreas's beta-cells from dying. They work by activating PPAR-gamma, which reduces cell death and amyloid buildup, thereby improving insulin secretion.

Resveratrol acts as a phytoestrogen by binding to estrogen receptors (ER-α and ER-β), but its affinity is 7000 times weaker than estradiol, and it acts as an antagonist in some tissues (e.g., uterus in rats) while showing agonist activity in others (e.g., MCF-7 breast cancer cells).

Resveratrol has a chemical structure similar to estrogen, but it binds to estrogen receptors very weakly. In some tissues, it may even block estrogen's effects. For most people, this interaction is negligible, but those with hormone-sensitive conditions should consult a doctor.

SIRT3 is a downstream target of PGC-1α and is essential for mediating the suppression of reactive oxygen species (ROS) and the stimulation of mitochondrial biogenesis in muscle cells.

This research highlights that SIRT3 is not just an isolated longevity gene but a key component of a larger system controlled by PGC-1α. To support mitochondrial health and reduce oxidative stress, interventions should focus on activating the upstream regulators (like PGC-1α) through exercise or metabolic stress, rather than just targeting SIRT3 in isolation.

PGC-1α stimulates SIRT3 gene expression by activating the SIRT3 promoter via an Estrogen-Related Receptor (ERR) binding element (ERRE).

Understanding that SIRT3 expression is driven by PGC-1α and ERRα suggests that lifestyle factors activating PGC-1α (like exercise or cold exposure) are likely the most effective natural ways to upregulate SIRT3.

GIP promotes fat accumulation and obesity by increasing lipoprotein lipase activity and energy storage in adipose tissue, whereas GLP-1 has no role in fat accumulation.

If you are managing obesity, understand that your body's natural GIP hormone may be encouraging fat storage, especially after high-fat meals. GLP-1 based therapies do not share this fat-promoting effect, which is a key difference between these two incretin pathways.

GIP promotes bone formation and inhibits osteoclast apoptosis, whereas GLP-1 inhibits bone resorption indirectly via calcitonin.

GIP may help protect bone density by keeping bone-building cells alive, while GLP-1 helps prevent bone loss by reducing breakdown. Both hormones support skeletal health through different pathways.

ApoB and LDL particle number (measured by NMR) are superior predictors of cardiovascular risk and residual risk on therapy compared to LDL cholesterol or non-HDL cholesterol in patients with cardiometabolic risk.

If your LDL is 'normal' but you still have high cardiovascular risk (due to diabetes or high triglycerides), ask your doctor about ApoB or LDL particle number. These tests may better predict your risk and guide treatment adjustments, though they may not be covered by insurance.

Lower serum levels of glycine and lysophosphatidylcholine (LPC) 18:2, combined with higher acetylcarnitine C2, predict the development of impaired glucose tolerance (IGT) and type 2 diabetes (T2D) years before clinical onset, independent of standard risk indicators like fasting glucose and HbA1c.

Current standard blood tests (fasting glucose, HbA1c) may not detect metabolic risk until it is advanced. Emerging research suggests that specific metabolite levels (glycine, LPC, acetylcarnitine) can predict diabetes risk years in advance. If you have risk factors, discuss advanced metabolic screening with your provider, as early detection allows for lifestyle interventions (diet/exercise) that can prevent or delay the onset of Type 2 Diabetes.

SIRT3 activation in brown adipocytes enhances mitochondrial function and thermogenesis by upregulating PGC-1α and UCP1, leading to increased oxygen consumption and reduced reactive oxygen species.

While you cannot directly 'dose' SIRT3, this research highlights that caloric restriction and cold exposure naturally upregulate SIRT3 in brown fat. This suggests that incorporating cold exposure (e.g., cold showers) and managing caloric intake may support mitochondrial health and thermogenesis via this pathway.

The Triglyceride-Glucose-Body Mass Index (TyG-BMI) is a superior, simple, and clinically useful surrogate marker for identifying insulin resistance in nondiabetic individuals compared to traditional lipid ratios, visceral adiposity indices, and other TyG-based variants.

If you are concerned about metabolic health but have normal blood sugar, ask your doctor to calculate your TyG-BMI. It is calculated by multiplying your fasting triglycerides and fasting glucose levels (converted to natural log) and then multiplying by your Body Mass Index. This single number is a highly accurate predictor of insulin resistance, often outperforming waist measurements or standard lipid ratios, allowing for early lifestyle interventions before diabetes or heart disease develops.

Elevated plasma alpha-hydroxybutyrate (a-HB) serves as an early, independent biomarker for identifying insulin resistance and impaired glucose tolerance in nondiabetic individuals, preceding clinical diagnosis.

If you are nondiabetic but concerned about metabolic health, standard glucose tests might miss early insulin resistance. Research indicates that measuring alpha-hydroxybutyrate (a-HB) in fasting plasma can identify insulin resistance and glucose intolerance earlier than standard tests, independent of BMI and age. This biomarker reflects underlying oxidative stress and lipid oxidation associated with insulin resistance.

Uric acid induces hepatic steatosis by generating mitochondrial oxidative stress, which inhibits aconitase, leading to citrate accumulation and subsequent de novo lipogenesis.

High fructose intake generates uric acid in the liver, which causes oxidative stress and fat accumulation. Lowering uric acid (e.g., via allopurinol in hyperuricemic patients) can reduce liver fat. For the general population, reducing fructose/sugar intake may prevent this uric acid-mediated pathway.

Psychological stress accelerates telomere shortening through increased oxidative stress and reduced telomerase activity, effectively aging cells by approximately 10 years compared to non-stressed individuals.

Manage psychological stress through techniques like meditation or mindfulness, as chronic stress can accelerate cellular aging by shortening telomeres.

Lactate acts as a signaling molecule ('lactormone') that regulates gene expression, mitochondrial biogenesis, and metabolic partitioning through mechanisms including histone lactylation and receptor binding.

Regular exercise increases lactate, which signals your body to build more mitochondria and improve metabolic health. This is a beneficial adaptive response, not a sign of damage.

In upper body obesity, the failure of subcutaneous fat to suppress free fatty acid (FFA) release in response to insulin/meal ingestion is the primary driver of elevated systemic FFA concentrations, which in turn cause insulin resistance in muscle, pancreas, and liver.

If you have upper body obesity, your subcutaneous fat cells are failing to listen to insulin, leaking fatty acids into your blood even after you eat. This leak causes insulin resistance in your muscles and liver. Simply removing subcutaneous fat surgically won't fix this; you must reduce fat cell size through caloric deficit and exercise to restore the fat's ability to store fat properly.